The objective was to determine whether or not the limited use of urethral microscopy to diagnose asymptomatic and symptomatic non-chlamydial, non-gonococcal urethritis (NCNGU) in men is a cost-effective strategy to avert pelvic inflammatory disease (PID), ectopic pregnancy or infertility in female partners. Outputs from a transmission dynamic model of NCNGU in a population of 16-30 year olds in England simulating the number of consultations, PID cases and patients treated over time amongst others, were used along with secondary data to undertake a cost-effectiveness analysis carried out from a health care provider perspective. The main outcome measure was cost per case of PID averted. A secondary outcome measure was cost per major outcome averted, where a major outcome is a case of symptomatic PID, ectopic pregnancy, or infertility. Offering a limited number of asymptomatic men urethral microscopy was more effective than the current practice of no microscopy in terms of reducing the number of cases of PID with an incremental cost-effectiveness ratio of £15,700, meaning that an investment of £15,800 is required to avert one case of PID. For major outcomes averted, offering some asymptomatic men urethral microscopy was again found to be more effective than no microscopy, but here an investment of £49,900 is required to avert one major outcome. Testing asymptomatic men for NCNGU in a small number of genitourinary medicine settings in England is not cost-effective, and thus by maintaining the current practice of not offering this patient group microscopy, this continues to make savings for the health care provider.
Introduction
Over the past decade, there has been a change in the clinical investigation and management of men attending sexual health services in the UK. Previously, all men, regardless of symptoms, underwent urethral smears, a process by which a sample is taken from inside the urethra and Gram stained for examination by light microscopy. 1 This allowed for the immediate diagnosis of two conditions: presumptive gonorrhoea and non-gonococcal urethritis (inflammation of the urethra in the absence of gonorrhoea). Men with either of these conditions, and their sexual partners, were then offered immediate treatment with appropriate antibiotics whilst waiting several days for more definitive results.
With the widespread use of sensitive and specific non-invasive urine testing for Chlamydia and gonorrhoea, and in order to streamline services in line with emerging evidence that it is not needed, guidelines now recommend only performing urethral microscopy in symptomatic men. 1 A consequence of this change in practice is that asymptomatic men with urethritis, caused by neither Chlamydia nor gonorrhoea (known as non-chlamydial, non-gonococcal urethritis or NCNGU), no longer receive empirical antimicrobial therapy. Their sexual partners are also left untreated. However, at the time of the most recent national audit, 1 a small number of clinics continued to provide routine urethral microscopy to asymptomatic men, contrary to the guidelines.
The potential impact of this change in practice on costs and patients' outcomes is not clear and has not yet been explored in any depth. Asymptomatic urethritis has many causes, both infectious and non-infectious. 1 Notably, Mycoplasma genitalium is present in 8-10% of men with asymptomatic urethritis 1 and is associated with both cervicitis and pelvic inflammatory disease (PID) in women. 2 There is limited access to testing for M. genitalium in the UK and few men are tested for this organism. Therefore, whereas previously, men with asymptomatic urethritis secondary to M. genitalium and their partners may have received successful treatment as part of empirical therapy for urethritis, this is no longer the case.
The focus of this study is on the potential cost implications of this change in clinical practice assuming that some men with asymptomatic NCNGU have M. genitalium, which can have adverse and costly reproductive health outcomes in their female sexual partners. Specifically, the objective of this economic evaluation is to determine whether the screening landscape at the time of the last national audit, in which a small number of clinics continued to perform routine microscopy in asymptomatic men, is a cost-effective approach to diagnosing and treating asymptomatic NCNGU compared to the national guideline recommending not performing microscopy for this patient group. While it is acknowledged that there may be other causes of asymptomatic NCNGU other than M. genitalium, there is little robust evidence that some of these may lead to important potential consequences. A previous study by Saunders et al. 3 found a paucity of high quality evidence that asymptomatic NCNGU is associated with significant consequences for men or their sexual partners. Thus, this study only considers cases caused by M. genitalium.
Methods
In order to estimate the impact of testing and treatment on the future transmission of possible significant pathogens responsible for asymptomatic NCNGU it is necessary to use an appropriate modelling approach for infectious diseases which can describe the transmission of M. genitalium between individuals, namely a transmission dynamic model (TDM). 4, 5 In this study a TDM describing the transmission of M. genitalium in the population of 16-30 year olds in England was constructed in order to examine changes in the use of urethral microscopy in asymptomatic men in genitourinary medicine (GUM) clinics. Here, the model output provides a hypothetical model state for asymptomatic patients which are defined here as those who do not have any symptoms associated with M. genitalium but who may seek care following partner notification or who may spontaneously seek screening. This economic evaluation uses outputs from this model, along with secondary data describing resource use and takes the form of a cost-effectiveness analysis carried out from a health care provider perspective, with costs valued at 2014/2015 UK prices.
Model structure
The output used in this economic analysis is taken from a TDM which has been described in full elsewhere. 6 In brief, this is a compartmental transmission model of the natural history of M. genitalium, its diagnosis, and treatment levels, and thus only M. genitalium was considered in this cost-effectiveness analysis. Heterogeneous sexual behaviour is described in the model which was parameterised by behaviour data from a number of key UK surveys, national surveillance data, and with the natural history of NCNGU being informed from data in the literature. The model describes the incidence and prevalence of symptomatic and asymptomatic infection, PID, care-seeking behaviour due to symptoms, partner notification and the possibility of treatment failure. The uncertainty of the parameters in the model was also factored into the model parameterisation.
The time horizon for the economic analysis is 20 years, although this is subject to sensitivity analysis. It was felt that a time horizon longer than this would not be appropriate due to the inevitable changes to testing technology and approaches to offering sexually transmitted infection (STI) screening to the population in the future. A discount rate of 3.5% was applied to costs and outcomes in accordance with NICE guidelines. 7 All settings where sexual health services are provided were initially considered for inclusion in this analysis. However, guidelines detailing the specific pathways and resources used at different sexual health service settings were sparse with the most reliable clinical data and cost data found in the literature being related to general practice (GP) and GUM settings, with GP consultations being considered due to the possibility of referral onwards to GUM services for further management. In this study the methodological focus is narrowed to the diagnosis and treatment of NCNGU in GP and GUM clinics.
Testing pathways for economic analysis
Three different pathways are compared in terms of their resource use and costs, each representing alternative approaches to the testing and treatment of patients with asymptomatic NCNGU. These pathways represent: (1) the current recommended practice of not offering microscopy to asymptomatic men in GUM settings; (2) offering a small proportion (5%) of asymptomatic men microscopy (i.e. men attending a small number of GUM services); and (3) offering microscopy to all asymptomatic men attending all GUM services. These three pathways are referred to in this study as 'Current Recommended Practice', '5% Microscopy' and '100% Microscopy'.
Initially, a patient can be either infected or noninfected with M. genitalium and either symptomatic or asymptomatic. The patient may attend either a GP or a GUM clinic for testing. For those patients who attend a GP setting, all patients (asymptomatic and symptomatic) are tested for Chlamydia and gonorrhoea using a nucleic acid amplification test (NAAT) but none are offered microscopy. From the GP setting a proportion of the patients are then referred to a GUM clinic for further investigation and management, for example those who are symptomatic or have more complex sexual health needs.
In contrast, in the GUM setting the diagnostic pathway varies depending on which strategy is being considered and whether the patient presents with symptoms or not. For the 'Current Recommended Practice' strategy, microscopy is not offered to asymptomatic patients and these patients receive a NAAT test for Chlamydia and gonorrhoea only. All asymptomatic patients in all locations in the 'Current Recommended Practice' scenario receive a NAAT for Chlamydia and gonorrhoea only. In the '5% Microscopy' and '100% Microscopy' scenarios, 5% and 100% of male patients receive urethral smear microscopy at GUM clinics, respectively. During the course of the consultation all symptomatic patients in a GUM setting receive partner notification and condoms with the aim of identifying individuals for whom testing and treatment may be appropriate. The testing pathways considered in this study are shown in Figure 1 . In this analysis, treatment can be deemed either a success or failure. Successful treatment indicates that a patient is no longer infected with M. genitalium and cannot transmit infection to their sexual partners. Treatment failure indicates that there has been a failure of the drug treatment to clear M. genitalium. Female patients who fail treatment or who are not treated can develop PID, a proportion of which cases are treated. Untreated PID cases may go on to experience symptomatic PID, infertility, or experience an ectopic pregnancy.
Model assumptions and parameterisation
This cost-effectiveness analysis was parameterised through secondary sources which are described below. It was necessary to make some pragmatic clarifying assumptions in order to carry out the analysis; these are described in the online supplementary material.
The model parameters used in this analysis are shown in Table 1 .
Resource use and costs
The cost of partner notification was adjusted to 2014/15 prices using the pay and price index for Hospital & Community Health Services. Unit staff costs were obtained from Unit Costs of Health & Social Care (2015). 13 The unit costs of each resource used in this economic evaluation are described in the online supplementary material.
Outcomes
The main outcome measure for this evaluation is the additional cost incurred per case of PID averted. The second outcome measure is the additional cost incurred per major outcome averted (MOA), where a major outcome is defined as a case of symptomatic PID, case of ectopic pregnancy, or a case of infertility. All major outcomes are reported for completeness. The results presented here use the incremental cost-effectiveness ratio (ICER), which is the difference in costs between two options divided by the difference in their effects (which are the outcome measures described above).
Analysis
The base case scenario uses the mean results of 215 parameter sets from the dynamic transmission model and applies resource costs to obtain the baseline deterministic results for each of the three testing scenarios. 
Results
All results presented here are shown for a time horizon of 20 years with discounting unless otherwise stated. In all cases the costs are presented to the nearest thousand, and the outcomes to the nearest hundred. ICER values were calculated using the unrounded cost and outcome values with these then being rounded to the nearest 100.
Outcomes
As shown in Table 2 , providing microscopy to 5% of asymptomatic men in a GUM setting has a positive impact on cases of PID. That is, the number of PID cases is lower for 5% Microscopy compared to No Microscopy. Likewise 5% Microscopy coverage also has a positive impact on reducing the number of major outcomes. In the case of the 100% Microscopy scenario, this has a greater impact on reducing cases of PID and major outcomes compared to either 5% or No Microscopy.
Costs
When only considering costs, it can be seen that the cost of 5% Microscopy coverage is greater than No Microscopy, while 100% Microscopy coverage is the most costly approach. This indicates that any savings that might have been made as a result of a reduction in major outcomes are insufficient to make 5% Microscopy or 100% Microscopy cost saving.
Incremental results
For the outcome of a case of PID averted the ICER values are shown in Table 3 . It can be seen that 5% Microscopy is more effective than no microscopy and has an ICER of £15,700, meaning that an investment of £15,700 is required to avert one case of PID. For the outcome of MOA it can again be seen ( Table 3 ) that 5% Microscopy is more effective than no microscopy, but in this case an investment of £49,900 is required to avert one major outcome. In the case of 100% Microscopy, an investment of £16,300 is required to avert one case of PID, and £51,900 to avert one major outcome compared to 5% Microscopy.
Sensitivity analysis
The results of the sensitivity analysis are described in the online supplementary material.
Discussion

Principal findings
This economic evaluation utilized the output from a TDM to estimate whether providing limited microscopy coverage to asymptomatic men to test for NCNGU at a limited number of GUM services Table 2 . Baseline results for the three strategies for cases of PID and all the major outcomes considered in this study. (as was the case at the time of the last national audit of practice 1 ) is a cost-effective option compared to the recommended current practice of its complete withdrawal.
This economic analysis was based on a principal outcome of cases of PID averted, and a secondary outcome of MOA (symptomatic PID, infertility, or ectopic pregnancy). The results at baseline indicate that performing urethral smear microscopy for approximately 5% of asymptomatic men attending GUM has an incremental cost of £15,700 per case of PID averted compared to no microscopy, meaning that this strategy invests approximately £15,700 to avoid one additional case of PID compared to a strategy of no routine microscopy screening where only symptomatic men are tested. Similarly 5% Microscopy coverage requires approximately £49,900 to avert one major outcome compared to a strategy of no routine microscopy screening where only symptomatic men are tested. Hypothetically, if recommended current practice were expanded to performing urethral smear microscopy for 100% of asymptomatic men attending GUM then this would have an additional cost of £16,300 per additional case of PID averted, and an additional £51,900 to avert an additional case of MOA compared to 5% Microscopy. These results also help to show that while conducting microscopy for 5% of asymptomatic men at GUM locations will avert PID and other major outcomes, at a population level it costs more to undertake the microscopy and associated patient management than it does to manage the adverse effects of not preventing the sequelae in a limited number of patients.
Across all the sensitivity analysis undertaken, 5% Microscopy coverage was never found to be cost saving but was always found to have a positive impact on reducing cases of PID and major adverse outcomes. Varying the outputs from the TDM provided a range of values for a the outcomes in this study. For a case of PID averted the ICER values ranged from £9600-£39,100, while for case of MOA the ICER values ranged from £30,500 to £124,400. By varying the time horizon of the analysis it was found that shorter time horizons made the intervention less cost-effective.
Strengths and weaknesses of study
This study has utilised the output from a well parameterised dynamic model that describes the transmission of M. genitalium in the population of males and females in England aged 16-30 years. Uncertainty in this model has been considered through the use of multiple parameter sets, while the results from this economic evaluation have been subject to extensive sensitivity analysis. Inevitably this has led to the range of plausible values being obtained from the economic model being quite wide, although this does help to give confidence to the validity of the conclusions that might be drawn from this model.
In this analysis only NCNGU due to M. genitalium has been considered in the analysis, and its scope has not been extended to other causes. There are some causes which are innocuous conditions that are not tested for, such as adenovirus, which are not known to cause reproductive sequelae in women. Consequently had these nonserious causes been taken into account, then it is very likely that the testing strategies would have been even less cost-effective than has been shown here.
A weakness of this study is the inability to conduct joint probabilistic sensitivity analysis (PSA) for both the economic parameters and the parameters utilized in the TDM. Although it was possible to conduct PSA for just the economic parameters while maintaining that output from the TDM at constant values, the results describing the probability of a strategy being below a specific acceptable threshold would be meaningless.
Comparisons with existing studies
To our knowledge this is the first economic analysis related to NCNGU in any setting, and thus comparisons with the results from similar economic studies are impossible.
Meaning of study
It is suggested that UK decision makers are unlikely to fund an intervention if it has an ICER value of £30,000/ quality adjusted life year (QALY) or more, 14 meaning that the extra health gain of an intervention as measured in QALYs must not cost more than £30,000 per QALY gained. However, as this study analysed outcomes in terms of cases of PID and major outcomes averted and not in terms of cost per QALY, there are no accepted threshold values which can be used to assess whether providing limited microscopy coverage to asymptomatic men is acceptable or not. This means that if an intervention is more costly and more effective than its comparator, we have no indication of whether the extra effectiveness will be worth paying for. It is therefore necessary to link the results here to the acceptance threshold values for the QALY in order to draw conclusions from this economic analysis.
Taking mean values from the TDM, the ICER for a case of PID averted and MOA were £15,700 and £49,900, respectively, for 5% Microscopy compared to no microscopy. Using the outcome of case of PID averted as an example, and taking into consideration the maximum acceptance threshold of £30,000/QALY used by the National Institute of Healthcare and Care Excellence (NICE) in England, for this ICER to be deemed cost-effective based on current accepted thresholds, a case of PID averted would have to result in a gain of 0.53 of a QALY. Alternatively, the implication is that having PID would have to be equivalent to losing more than six months of perfect health. Likewise for MOA this would have to be more than 1.67 QALYs, meaning that having a major outcome would have to be equivalent to losing more than 18 months of perfect health.
Even allowing for patient suffering and particularly the stress of infertility, current evidence suggests that these outcomes are not valued so extremely. Smith et al. 15 in a primary study based on a time trade off approach, asked respondents with a previous history of PID to value alternative conditions. The mean valuations for long-term health states associated with PID were: ectopic pregnancy 0.79 (standard deviation [SD] ¼ 0.34); pelvic pain 0.69 (SD ¼ 0.37); infertility 0.76 (SD ¼ 0.34). These values suggest that the mean QALY gain to avert a case of pelvic pain (the state with the reported greatest negative impact on quality of life [QoL] ) that lasted one year would be 0.31 QALYs. However as noted above for the results described here, for 5% Microscopy coverage to be cost-effective, a MOA must lead to a gain of more than 1 QALY, suggesting that the current practice of providing limited microscopy coverage for asymptomatic men is far from being cost-effective.
Given the comparisons described above, it can therefore be concluded that the recommended practice of reserving urethral microscopy for symptomatic men and not testing asymptomatic men is a cost-effective strategy and reintroducing ad-hoc testing for asymptomatic men in GUM locations is unlikely to be costeffective. Considering the results at baseline in this study, if ad-hoc microscopy testing for asymptomatic men were reintroduced into GUM locations then this would lead to over £5,000,000 (discounted) in costs over a 20-year period, which could then be better spent expanding testing and treatment regimens for different diseases which are more cost-effective. However the results shown in this study do very much represent the current situation in terms of testing for M. genitalium, indeed, as diagnostic technology moves forward, it is likely that routine screening for M. genitalium will become more viable in terms of its effectiveness at improving patient outcomes and cost-effectiveness.
Unanswered questions and future research
One of the major issues related to any testing and diagnosis strategy is the impact of the testing pathway on patients. Patients may suffer from anxiety while waiting for the result of a test, or may incur societal costs as a result of having to take time off work to attend for testing. There are also issues specific to the context of STIs where patients may be worried about the stigma of attending for testing and the difficulties surrounding partner notification for NCNGU. In the testing and diagnosis context, future work should focus on these issues, in order to better quantify their impact on patients with the goal of including the impact of these issues in economic studies such as this in order to better describe the true impact of the complete testing pathway on patients. Furthermore, this study has not considered the possibility of targeting high-risk asymptomatic males with a NAAT for M. genitalium, e.g. males that have a sexual partner with a risk factor for STI, males that undertake high-risk sexual behaviour, or males that have had sexual contact with persons with an STI or PID. This could be considered in future work, since targeting these individuals is likely to have a positive impact on disease transmission and therefore cost-effectiveness. Finally, we recognise that our understanding of the urethral microbiome and the significance of micro-organisms found in the male urethra is incomplete. It may be that other organisms also cause male urethritis and are associated with adverse reproductive consequences in women. As information becomes available, future work can take this new knowledge and update our approach to provide more robust cost-effectiveness estimates.
Key messages
. Current clinical recommendations for the UK are that urethral microscopy should not be offered to asymptomatic men attending GUM clinics for diagnosis of NCNGU. . Offering microscopy at very low level of coverage where a small number of GUM services in England routinely offered asymptomatic men urethral microscopy for NCNGU is not cost-effective and wastes resources which could be put to better use elsewhere. . Complete withdrawal of microscopy testing for asymptomatic men in a GUM setting could save over £5,000,000 (discounted) over a 20-year period.
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